Last reviewed · How we verify
NP101 - Sumatriptan iontophoretic transdermal patch
NP101 delivers sumatriptan through the skin via iontophoresis, a technique using electrical current to enhance transdermal penetration, allowing rapid absorption without needles or oral administration.
NP101 delivers sumatriptan through the skin via iontophoresis, a technique using electrical current to enhance transdermal penetration, allowing rapid absorption without needles or oral administration. Used for Acute migraine with or without aura.
At a glance
| Generic name | NP101 - Sumatriptan iontophoretic transdermal patch |
|---|---|
| Also known as | Sumatriptan |
| Sponsor | NuPathe Inc. |
| Drug class | 5-HT1B/1D receptor agonist (triptan) |
| Target | 5-HT1B receptor, 5-HT1D receptor |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
Sumatriptan is a selective serotonin 5-HT1B/1D receptor agonist that constricts cranial blood vessels and inhibits neuropeptide release to relieve migraine headaches. The iontophoretic transdermal patch technology uses a small electrical current to actively transport the drug across the skin barrier, enabling faster onset of action compared to oral formulations while avoiding gastrointestinal absorption variability.
Approved indications
- Acute migraine with or without aura
Common side effects
- Application site reactions (erythema, pruritus)
- Chest pain or pressure
- Dizziness
- Paresthesia
- Flushing
Key clinical trials
- Compare PK and Bioavailability of 2 NP101 Patches With Oral Imitrex in Healthy Adults (PHASE1)
- An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months (PHASE3)
- An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months (PHASE3)
- The Efficacy and Tolerability of NP101 Patch in the Treatment of Acute Migraine (PHASE3)
- Phase I Open Label Single-Dose Study to Compare the Pharmacokinetics of NP101 Healthy Volunteers (PHASE1)
- Phase I Study to Compare NP101(Sumatriptan Iontophoretic Transdermal Patch) With Three Formulations of Imitrex® (PHASE1)
- Phase I, Open Label, Single-Dose, Four Way Crossover Study to Compare the PK of NP101 With Oral Imitrex® (50mg) in Migraine Subjects During an Acute Migraine Attack and During a Non-Migraine Period (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: